Advertisement

Journal of Analytical Chemistry

, Volume 73, Issue 7, pp 674–678 | Cite as

Determination of Andarine (S-4), a Selective Androgen Receptor Modulator, and Ibutamoren (MK-677), a Nonpeptide Growth Hormone Secretagogue, in Urine by Ultra-High Performance Liquid Chromatography with Tandem Mass-Spectrometric Detection

  • E. V. DmitrievaEmail author
  • A. Z. Temerdashev
  • A. A. Azaryan
  • E. M. Gashimova
Articles

Abstract

A procedure for the determination of a selective androgen receptor modulator andarine (S-4) and a nonpeptide growth hormone secretagogue ibutamoren (MK-677) in urine has been developed including sample preparation by the “dilute-and-shoot” procedure, separation of analytes by ultra-high performance liquid chromatography in the gradient elution mode, and mass-spectrometric detection with heated electrospray ionization. The limits of detection are in the range of 0.5–2.5 ng/mL, the calibration curves are linear in the range of 2.5–250 ng/mL for andarine and 5–250 ng/mL for ibutamoren. The proposed procedure was used for the analysis of urine samples obtained from volunteers after a single administration of these drugs containing 15 mg of active substances.

Keywords

ultra-high performance liquid chromatography tandem mass spectrometry selective androgen receptor modulators nonpeptide growth hormone secretagogue andarine ibutamoren “dilute-and-shoot” doping control 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chen, J., Kim, J., and Dalton, J.T., Mol. Interventions, 2012, vol. 5, no. 3, p.173.CrossRefGoogle Scholar
  2. 2.
    Aikawa, K., Miyawaki, T., Hitaka, T., Imai, Y.N., Hara, T., Miyazaki, J., Yamaoka, M., Kusaka, M., Kanzaki, N., Tasaka, A., Shiraishi, M., and Yamamoto, S., Bioorg. Med. Chem., 2015, vol. 23, no. 10, p. 2568.CrossRefPubMedGoogle Scholar
  3. 3.
    World Anti-Doping Agency, The World Anti-Doping Code, The 2008 Prohibited List, International Standard, 2008. www.wada-ama.org/sites/default/files/resources/files/WADA_Prohibited_List_2008_EN.pdf. Accessed May 7, 2017.Google Scholar
  4. 4.
    Gao, W., Kim, J., and Dalton, J.T., Pharm. Res., 2006, vol. 23, no. 8, p. 1641.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Thevis, M., Kohler, M., Maurer, J., Schlorer, N., Kamber, M., and Schanzer, W., Rapid Commun. Mass. Spectrom., 2007, vol. 21, no. 21, p. 3477.CrossRefPubMedGoogle Scholar
  6. 6.
    Gao, W. and Dalton, J.T., Drug Discovery Today, 2007, vol. 12, nos. 5–6, p.241.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Narayanan, R., Mohler, M.L., Bohl, C.E., Miller, D.D., and Dalton, J.T., Nucl. Recept. Signaling, 2008, vol. 6, p. e010.CrossRefGoogle Scholar
  8. 8.
    Grata, E., Perrenoud, L., Saugy, M., and Baume, N., Forensic Sci. Int., 2011, vol. 213, nos. 1–3, p.104.CrossRefPubMedGoogle Scholar
  9. 9.
    Starcevic, B., Ahrens, B.D., and Butch, A.W., Drug Test. Anal., 2013, vol. 5, no. 5, p.377.CrossRefPubMedGoogle Scholar
  10. 10.
    Thevis, M., Thomas, A., Fußhöller, G., Beuck, S., Geyer, H., and Schänzer, W., Rapid Commun. Mass. Spectrom., 2010, vol. 24, no. 15, p. 2245.CrossRefPubMedGoogle Scholar
  11. 11.
    Patchett, A.A., Nargund, R.P., Tata, J.R., Chen,M.H., Barakat, K.J., Johnston, D.B., Cheng, K., Chan, W.W., Butler, B., and Hickey, G., Proc. Natl. Acad. Sci. U. S. A., 1995, vol. 92, no. 15, p. 7001.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Smith, R.G., Endocr. Rev., 2005, vol. 26, no. 3, p.346.CrossRefPubMedGoogle Scholar
  13. 13.
    Sobolevsky, T., Krotov, G., Dikunets, M., Nikitina, M., Mochalova, E., and Rodchenkov, G., Drug Test. Anal., 2014, vol. 6, nos. 11–12, p. 1087.CrossRefPubMedGoogle Scholar
  14. 14.
    Sobolevsky, T., Prasolov, I., and Rodchenkov, G., Recent Adv. Doping Anal., 2013, p.182.Google Scholar
  15. 15.
    Identification criteria for qualitative assays incorporating column chromatography and mass spectrometry, WADA Technical Document TD2015IDCR, 2015. www.wada-ama.org/sites/default/files/resources/files/td2015idcr_-_eng.pdf. Accessed May 7, 2017.Google Scholar
  16. 16.
    Cappiello, A., Famiglini, G., Palma, P., and Trufelli, H., J. Liq. Chromatogr., 2010, vol. 33, p. 1067.CrossRefGoogle Scholar
  17. 17.
    Van Eeckhaut, A., Lanckmans, K., Sarre, S., Smolders, I., and Michotte, Y., J. Chromatogr. B: Anal. Technol. Biomed. Life Sci., 2009, vol. 877, no. 23, p. 2198.CrossRefGoogle Scholar
  18. 18.
    Taylor, P.J., Clin. Biochem., 2005, vol. 38, no. 4, p.328.CrossRefPubMedGoogle Scholar
  19. 19.
    Deventer, K., Pozo, O.J., Verstraete, A.G., and Van Eenoo, P., TrAC, Trends. Anal. Chem., 2014, vol. 55, p.1.CrossRefGoogle Scholar
  20. 20.
    FDA Guidance for Industry: Bioanalytical Method Validation, Rockville: US Department of Health and Human Services, Food and Drug Administration (FDA), 2013. https://doi.org/www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf. Accessed May 7, 2017.

Copyright information

© Pleiades Publishing, Ltd. 2018

Authors and Affiliations

  • E. V. Dmitrieva
    • 1
    Email author
  • A. Z. Temerdashev
    • 1
  • A. A. Azaryan
    • 1
  • E. M. Gashimova
    • 1
  1. 1.Kuban State UniversityKrasnodarRussia

Personalised recommendations